Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (3064)	9/14/2005 1:20:14 PM
From: Icebrg	Read Replies (2) \| Respond to of 12215

Boronate at the MLNM YMB suggests: My two cents by: boronate 09/14/05 12:46 pm Msg: 67543 of 67544 My opinion is that Celg will get on October 7 an approvable letter from the FDA, pending the Phase III trial to define the role of 5 mg starting dose. The committee was adamant on this point with a 13-2 no vote on the proposed starting dose. This will preclude Rev coming into the market for MDS for a long time. The marketing will the depend on the yet to be submitted NDA for myeloma. Erik